An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
PolyPid (Nasdaq: PYPD) will report its first quarter 2024 financial results and operational highlights on May 8, 2024. The company aims to improve surgical outcomes and will host a conference call and webcast to discuss the results and business operations.
PolyPid (Nasdaq: PYPD) pubblicherà i risultati finanziari del primo trimestre del 2024 e gli highlights operativi l'8 maggio 2024. L'obiettivo della società è migliorare i risultati chirurgici e si terrà una conferenza telefonica e un webcast per discutere dei risultati e delle operazioni aziendali.
PolyPid (Nasdaq: PYPD) informará sobre sus resultados financieros del primer trimestre de 2024 y los aspectos destacados operativos el 8 de mayo de 2024. La compañía tiene como objetivo mejorar los resultados quirúrgicos y realizará una llamada de conferencia y una transmisión web para discutir los resultados y las operaciones comerciales.
PolyPid (나스닥: PYPD)는 2024년 1분기 재무 결과와 운영 하이라이트를 2024년 5월 8일에 보고할 예정입니다. 이 회사는 수술 결과를 개선하고자 하며, 결과 및 비즈니스 운영에 대해 논의하기 위한 컨퍼런스 콜과 웹캐스트를 개최할 것입니다.
PolyPid (Nasdaq: PYPD) présentera ses résultats financiers pour le premier trimestre de 2024 et les points forts de ses opérations le 8 mai 2024. L'entreprise vise à améliorer les résultats chirurgicaux et organisera une conférence téléphonique ainsi qu'une webdiffusion pour discuter des résultats et des opérations commerciales.
PolyPid (Nasdaq: PYPD) wird am 8. Mai 2024 seine Finanzergebnisse für das erste Quartal 2024 sowie betriebliche Höhepunkte bekannt geben. Das Unternehmen zielt darauf ab, chirurgische Ergebnisse zu verbessern und wird eine Telefonkonferenz sowie ein Webcast veranstalten, um die Ergebnisse und Geschäftsaktivitäten zu besprechen.
Positive
None.
Negative
None.
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.
Contacts:
PolyPid Ltd. Ori Warshavsky COO – US 908-858-5995 IR@Polypid.com
When will PolyPid report its first quarter 2024 financial results?
PolyPid will report its first quarter 2024 financial results on May 8, 2024.
What is the ticker symbol for PolyPid?
The ticker symbol for PolyPid is PYPD.
How can I listen to the conference call and webcast?
You can listen to the conference call and webcast on Wednesday, May 8, 2024, at 8:30 AM Eastern Time. Register in advance for the call or listen via the webcast.
What is the focus of PolyPid as a company?
PolyPid is a late-stage biopharma company aiming to improve surgical outcomes.
polypid®, a specialty pharmaceutical company, develops and manufactures products based on its plex™ technology. so far, 70 patients have been treated in clinical trials with polypid’s anti-infection products demonstrating safety and efficacy. polypid is in the process of submitting its lead product for phase-iii trial in the us and eu. plex™ is able to optimize drugs' therapeutic performance and clinical outcomes. plex™-based protected drug reservoir is implanted directly into the body’s target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. polypid’s pipeline focuses on 3 products: d-plex™ - intended for prevention and treatment of surgical infections caused by bacteria. its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. the product is currently undergoing clinical studies at several medical centers. bonypid®-1000 - designed to e
